Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | PROPHECY trial: AR-V7 CTCs as a biomarker in mCRPC

Andrew Armstrong • 1 Jun 2018
ASCO 2018
Genitourinary Cancer Prostate Cancer Abiraterone Enzalutamide
PROPHECY

Andrew Armstrong, MD, from Duke University, Durham, NC, speaks from the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL. Dr Armstrong shares details of the PROPHECY trial (NCT02269982), which is investigating AR-V7 on circulating tumor cells as a prospective predictor in men with metastatic castration-resistant prostate cancer (mCRPC).

More from Andrew Armstrong

1:25
Potential of CTCs for biomarker detection in prostate cancer
Andrew Armstrong • 16 Sep 2022
2:33
VISION: association between PSA decline & clinical outcomes in patients with mCRPC
Andrew Armstrong • 16 Sep 2022
1:53
The evolving role of PARP inhibitors in mCRPC
Andrew Armstrong • 13 Sep 2022
3:47
Elucidating HRRm status in patients with mCRPC in the PROpel trial
Andrew Armstrong • 13 Sep 2022

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals